Moderna has filed complaints in the US and Germany claiming that the mRNA technology used to make Pfizer and BioNTech's Comirnaty vaccine infringes multiple patents that cover its own Spikevax shot.

MRNA opened at $34.62 on Thursday. The company has a market capitalization of $13.36 billion, a P/E ratio of -3.73 and a beta of 1.86. The stock has a fifty day moving average of $35.94 and a 200 ...

Steward Partners Investment Advisory LLC cut its holdings in shares of Moderna, Inc. (NASDAQ ... and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise ...

The FDA has approved new versions of Pfizer/BioNTech's Comirnaty and Moderna's Spikevax COVID-19 vaccines that target the Omicron KP.2 strain of SARS-CoV-2 which was dominant in the US in recent ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

US stocks (^DJI, ^IXIC, ^GSPC) capped off Tuesday's session in negative territory, snapping the last two trading days' worth of gains. Yahoo Finance markets and data editor Jared Blikre highlights ...

After hours: 17 March at 7:59:55 pm GMT-4 Loading Chart for MRNA ...